Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
12 Jan 2020
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

Epidural oxycodone accelerates onset, prolongs duration of analgesia during labour

21 Dec 2019

Using oxycodone in addition to ropivacaine confers benefits for the timing of onset and duration of epidural analgesia during labour without contributing to an increase in adverse neonatal outcomes, according to the results of a trial. However, it may lead to a greater incidence of maternal pruritus.

Eighty nulliparous parturients requiring epidural analgesia were randomly assigned to the following treatment groups: active, which received 0.2 mg/mL oxycodone plus 0.1% ropivacaine, and control, which received 0.1% ropivacaine alone.

The effect of treatment was assessed in relation to the following outcomes: onset time and duration of analgesia, duration of labour stages, delivery outcome, analgesic effect, Bromage scores, blood pressure, heart rate and neonatal Apgar scores. Researchers also analysed umbilical arterial blood and recorded any side effects.

Compared with the control group, the active group had lower visual analogue scale (VAS) of pain at 2 and 4 hours after analgesia (p=0.021 and p=0.018, respectively), as well as 10 cm cervical dilatation (p=0.009).

The onset of analgesia occurred earlier among patients in the active group (mean, 13.3 vs 14.9 minutes; p=0.032). There were no marked between-group differences observed in the duration of labour stages, delivery outcome, Bromage score, neonatal Apgar score and umbilical arterial blood pH.

Moreover, the duration of analgesia was significantly longer in the active vs control group (mean, 326.2 vs 68.4 minutes; p=0.000), although the incidence of pruritus was numerically higher in the former (10 percent vs 0 percent; p=0.115).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
12 Jan 2020
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.